Trial
NCT04650451
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors
Phase ISUSPENDEDSAFETYConfidence: HIGH
Sponsor
Bellicum Pharmaceuticals
Collaborators
—
Condition
HER-2 Gene Amplification
Intervention
chimeric antigen receptor (CAR) T cell therapy
Why stopped
Due to a Dose Limiting Toxicity in another sister trial with same technology.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-04-20